Literature DB >> 22813921

Combined values of serum albumin, C-reactive protein and body mass index at dialysis initiation accurately predicts long-term mortality.

Ryo Takahashi1, Yasuhiko Ito, Hiroshi Takahashi, Hideki Ishii, Hirotake Kasuga, Masashi Mizuno, Yasuhiro Suzuki, Yukio Yuzawa, Shoichi Maruyama, Toyoaki Murohara, Enyu Imai, Seiichi Matsuo.   

Abstract

BACKGROUND: Protein-energy wasting and chronic inflammation are prevalent in patients with end-stage renal disease (ESRD). We investigated the combination of serum albumin, C-reactive protein (CRP) and body mass index (BMI) at initiation of hemodialysis therapy as a predictor of all-cause and cardiovascular disease (CVD) mortality in Japanese ESRD patients.
METHODS: A total of 1,228 consecutive Japanese ESRD patients on hemodialysis therapy were enrolled and followed for up to 10 years. Patients were divided into quartiles according to levels of albumin, CRP and BMI. Furthermore, to clarify the joint role of these factors, albumin <3.5 g/dl, CRP >4.0 mg/l and BMI <19.6 were defined as risk factors using receiver operating characteristic analysis; thereafter, patients were divided into groups according to the positive number of these factors.
RESULTS: Adjusted hazard ratios (HRs) for lower serum albumin, elevated CRP and lower BMI for 10-year all-cause mortality were 1.97, 3.13 and 2.61, respectively. Regarding the combination of these variables, adjusted HRs for mortality were 2.31, 4.28 and 8.07, respectively, in patients having any one factor, any two factors and all three factors. The C-index for an established risk model with these three positive markers was the most accurate for predicting mortality (0.768), as compared to other models with one or two markers. Similar results were seen for CVD mortality.
CONCLUSIONS: Serum albumin, CRP and BMI at the start of hemodialysis therapy were able to individually stratify the risk of long-term mortality in ESRD patients. Furthermore, a combination of these variables could more accurately predict mortality.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22813921     DOI: 10.1159/000339940

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  16 in total

1.  Combination of low body mass index and serum albumin level is associated with chronic kidney disease progression: the chronic kidney disease-research of outcomes in treatment and epidemiology (CKD-ROUTE) study.

Authors:  Hiroaki Kikuchi; Eiichiro Kanda; Shintaro Mandai; Masanobu Akazawa; Soichiro Iimori; Katsuyuki Oi; Shotaro Naito; Yumi Noda; Takayuki Toda; Teiichi Tamura; Sei Sasaki; Eisei Sohara; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2016-02-26       Impact factor: 2.801

2.  C-reactive protein and other markers of inflammation in hemodialysis patients.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2013

3.  High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.

Authors:  Yueqiang Wen; Qunying Guo; Xiao Yang; Xianfeng Wu; Shaozhen Feng; Jiaqing Tan; Ricong Xu; Xueqing Yu
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

4.  Association Between Serum Albumin Levels and Obesity and Risk of Developing Chronic Kidney Disease Using Data from the Korean Multi-Rural Communities Cohort (MRCohort) Population Database.

Authors:  Kwang Ho Mun
Journal:  Med Sci Monit       Date:  2021-08-16

5.  Importance of simultaneous evaluation of multiple risk factors for hemodialysis patients' mortality and development of a novel index: dialysis outcomes and practice patterns study.

Authors:  Eiichiro Kanda; Brian A Bieber; Ronald L Pisoni; Bruce M Robinson; Douglas S Fuller
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

6.  Development and validation of a predictive mortality risk score from a European hemodialysis cohort.

Authors:  Jürgen Floege; Iain A Gillespie; Florian Kronenberg; Stefan D Anker; Ioanna Gioni; Sharon Richards; Ronald L Pisoni; Bruce M Robinson; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

7.  Effect of Vitamin C Supplementation on C-reactive Protein Levels in Patients Undergoing Hemodialysis: A Randomized, Double Blind, Placebo-Controlled Study.

Authors:  Vajihe Biniaz; Mehdi Sadeghi Shermeh; Abbas Ebadi; Ali Tayebi; Behzad Einollahi
Journal:  Nephrourol Mon       Date:  2013-11-27

8.  Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact.

Authors:  Masaaki Konishi; Junichi Ishida; Jochen Springer; Stefan D Anker; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-04-12       Impact factor: 12.910

9.  Consequences of increasing convection onto patient care and protein removal in hemodialysis.

Authors:  Nathalie Gayrard; Alain Ficheux; Flore Duranton; Caroline Guzman; Ilan Szwarc; Fernando Vetromile; Chantal Cazevieille; Philippe Brunet; Marie-Françoise Servel; Àngel Argilés; Moglie Le Quintrec
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

10.  Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease.

Authors:  Akihiko Nakamura; Ryo Kodera; Noriko Sakamoto; Haruyo Ujike; Jun Wada; Kenichi Shikata; Hirofumi Makino
Journal:  Diabetol Int       Date:  2018-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.